Cell Line Origin
Human small cell lung cancer, drug-resistant
Cell Line Description
NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.
Drug-resistance studies, small cell lung cancer
RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37ºC; resuscitate in drug-free medium until first passage.
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.